New Data Phase 3 Data Confirms Robust Efficacy and Long-Term Prevention Effects of AstraZeneca (AZN) AZD7442
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
AstraZeneca's (AZN) LOKELMA Granted Fast Track Designation in the US to Reduce Cardiovascular Outcomes in Patients on Chronic Hemodialysis With Hyperkalemia
November 17, 2021 10:03 AM ESTAstraZeneca has been granted Fast Track Designation in the United States (US) for the development of LOKELMA® (sodium zirconium cyclosilicate) to reduce arrhythmia-related cardiovascular outcomes in patients on chronic hemodialysis with recurrent hyperkalemia (HK). The designation is based on the potential of LOKELMA to reduce serious adverse CV outcomes in this patient population, addressing a significant unmet medical need. This is being investigated in the ongoing Phase III DIALIZE-Outcomes trial.
HK is a prevalent condition in patients with chronic kidney disease (CKD) and heart failure (HF), affecting 24% to 48% of patients with moderate to advanced... More
AstraZeneca (AZN) Has Supplied Two Billion Doses of COVID-19 Vaccine in 11 Months
November 16, 2021 6:00 AM ESTAstraZeneca (NASDAQ: AZN) and its partners have released for supply two billion doses of their COVID-19 vaccine to more than 170 countries across every continent on the planet in the last 11 months.
Approximately two-thirds of these have gone to low- and lower-middle-income countries, including more than 175 million doses delivered to 130 countries through the COVAX Facility.
This milestone comes just over 18 months after AstraZeneca and Oxford University formed their landmark partnership for the global development and distribution... More
Credit Suisse Reiterates Outperform Rating on AstraZeneca (AZN:LN) (AZN)
November 16, 2021 5:09 AM ESTCredit Suisse analyst Trung Huynh reiterated an Outperform rating and GBP90.00 price target on AstraZeneca (AZN:LN) (NASDAQ: AZN).
... More